Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples